Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers14133285
Title: | SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes | Authors: | Lee, Victor Ho-Fun Tsang, Raymond King-Yin Lo, Anthony Wing Ip Chan, Sum-Yin Chung, Joseph Chun-Kit Tong, Chi-Chung Leung, To-Wai Kwong, Dora Lai-Wan |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology SMARCB1-deficient INI1-deficient sinonasal paranasal tazemetostat treatment outcomes systematic review SAC TUMOR DIFFERENTIATION PROTON-BEAM THERAPY UNDIFFERENTIATED CARCINOMA OPEN-LABEL INI1 EXPRESSION MODALITY HEAD TAZEMETOSTAT EXPERIENCE EZH2 |
Issue Date: | 1-Jul-2022 | Publisher: | MDPI | Citation: | Lee, Victor Ho-Fun, Tsang, Raymond King-Yin, Lo, Anthony Wing Ip, Chan, Sum-Yin, Chung, Joseph Chun-Kit, Tong, Chi-Chung, Leung, To-Wai, Kwong, Dora Lai-Wan (2022-07-01). SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes. CANCERS 14 (13). ScholarBank@NUS Repository. https://doi.org/10.3390/cancers14133285 | Abstract: | (1) Background: SMARCB1 (INI-1)-deficient sinonasal carcinoma is a rare sinonasal malig-nancy; since its discovery and description in 2014, less than 200 cases have been identified. It is almost impossible to perform randomized-controlled trials on novel therapy to improve treatment outcomes in view of its rarity. We performed a systematic review of all the published case reports/series and included our patients for survival analysis. (2) Methods: In this systematic review, we searched from PubMed-MEDLINE, EMBASE, Scopus, Cochrane Library, CINAHL, and Google Scholar for individual patient data to identify and retrieve all reported SMARCB1-deficient sinonasal carci-noma. Clarification on treatment details and the most updated survival outcomes from all authors of the published case reports/series were attempted. Survival analysis for overall survival (OS) and identification of OS prognostic factors were performed. This systematic review was registered with PROSPERO (CRD42022306671). (3) Results: A total of 67 publications were identified from the systematic review and literature search. After excluding other ineligible and duplicated publications, 192 patients reported were considered appropriate for further review. After excluding duplicates and patients with incomplete pretreatment details and survival outcomes, 120 patients were identified to have a complete set of data including baseline demographics, treatment details, and survival outcomes. Together with 8 patients treated in our institution, 128 patients were included into survival analysis. After a median follow up of 17.5 months (range 0.3–149.0), 50 (46.3%) patients died. The 1-year, 2-year and 3-year OS rates were 84.3% (95% CI % 77.6–91.0), 62.9% (95% CI 53.1–72.7), and 51.8% (95% CI 40.8–62.8), respectively, and the median OS was 39.0 months (95% CI 28.5–49.5). Males (p = 0.029) and T4b disease (p = 0.013) were significant OS prognostic factors in univariable analysis, while only T4b disease (p = 0.017) remained significant in multivariable analysis. (4) Conclusions: SMARCB1-deficient sinonasal carcinoma is an extremely aggressive sinonasal malignancy with a dismal prognosis. Early diagnosis and a multimodality treatment strategy are essential for a better treatment and survival outcome. | Source Title: | CANCERS | URI: | https://scholarbank.nus.edu.sg/handle/10635/238342 | ISSN: | 2072-6694 | DOI: | 10.3390/cancers14133285 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma A Systematic Review and Pooled Analysis of Treatment Outcomes.pdf | 948.48 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.